On October 20, 2016 Synaffix BV reported it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect and HydraSpace site-specific antibody-drug conjugate technologies (Press release, Synaffix, OCT 20, 2016, View Source [SID1234522092]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs.
Floris van Delft, CSO at Synaffix said,
"We are delighted that ADC Therapeutics has recognized the value of our proprietary antibody-drug conjugate technologies and has elected to incorporate Synaffix technology into one of its preclinical programs."
"The experience of Synaffix and its partners has consistently confirmed that, in preclinical models, our proprietary GlycoConnect and HydraSpace technologies significantly improved both efficacy and safety as compared to other mainstream site-specific conjugation approaches."
"We look forward to working closely with the ADC Therapeutics team to advance these promising therapeutics to the patients who need them."
Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis.
About GlycoConnect and HydraSpace
The Synaffix technology platforms include GlycoConnect, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation reagents, and HydraSpace, the antibody-drug conjugate enhancing spacer technology.
GlycoConnect was shown to be capable of significantly enhancing the therapeutic index of an antibody-drug conjugate on its own. The highly polar properties of HydraSpace improve the solubility and stability of the payload and the resulting antibody-drug conjugate product, thus enhancing further the therapeutic index of the antibody-drug conjugate.
Both technologies have demonstrated compatibility with all antibody-drug conjugate payload classes and all IgG isotypes without requiring antibody engineering.